Financials in USD. Standardized financial statements.
A compact view of how Editas Medicine, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $40.52M | $32.31M | $78.12M | $19.71M | $25.54M | $90.73M | $20.53M | $31.94M | $13.73M | $6.05M |
| Revenue Growth? | +25.4% | -58.6% | +296.3% | -22.8% | -71.8% | +341.9% | -35.7% | +132.6% | +126.8% | 0.0% |
| Cost of Revenue? | $0 | $0 | $6.06M | $6.34M | $5.05M | $158.00M | $96.90M | $90.65M | $83.16M | $56.98M |
| Gross Profit? | $40.52M | $32.31M | $72.06M | $13.38M | $20.49M | -$67.26M | -$76.37M | -$58.72M | -$69.43M | -$50.93M |
| Gross Margin? | +100.0% | +100.0% | +92.2% | +67.9% | +80.2% | -74.1% | -372.0% | -183.9% | -505.8% | -841.3% |
| Operating Expenses? | $139.86M | $283.47M | $241.24M | $239.32M | $213.64M | $67.58M | $64.56M | $145.66M | $133.66M | $103.24M |
| Operating Income? | -$99.34M | -$251.15M | -$169.18M | -$225.95M | -$193.15M | -$134.84M | -$140.92M | -$113.73M | -$119.93M | -$97.19M |
| EBITDA? | -$148.61M | -$233.11M | -$163.12M | -$219.61M | -$188.09M | -$130.88M | -$138.09M | -$110.47M | -$116.66M | -$96.07M |
| Income Before Tax | -$160.06M | -$237.09M | -$153.22M | -$220.43M | -$192.50M | -$115.98M | -$133.75M | -$109.95M | -$120.32M | -$97.18M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.12M | $0 |
| Net Income? | -$160.06M | -$237.09M | -$153.22M | -$220.43M | -$192.50M | -$115.98M | -$133.75M | -$109.95M | -$120.32M | -$97.18M |
| EPS? | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.47 | $-2.33 | $-2.98 | $-3.02 |
| Diluted EPS? | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.47 | $-2.33 | $-2.98 | $-3.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality